Patient View

Lundbeck appoints Tarek Samad as EVP, Head of Research & Development

Samad previously held senior research leadership positions at Immunitas Therapeutics, Sanofi and Pfizer

Lundbeck completes patient randomisation for phase 3 trial for multiple system atrophy treatment

The rare neurodegenerative disorder has no cure and no approved treatments

Trust and transparency in Pharma & healthcare: impact of the COVID-19 pandemic

While it is obvious that trust in life science and healthcare companies is suboptimal, exactly how to improve the public’s trust is unclear...

Impetus Digital

OPEN Health CSR Report 2019

Margot Hannah, Partner and Group Managing Director, and CSR lead at OPEN Health shares her thoughts on our latest report.

OPEN Health

Lundbeck drops Parkinson’s drug acquired in €905m deal

Disappointment after drug failed in a mid-stage clinical trial

Policy and public health: all the decisions we can’t see

January was a bad month for healthcare in China

Lundbeck gets US approval for migraine drug at heart of Alder takeover

US regulator clears CGRP inhibitor under Vyepti trade name

Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

Continues to bulk up its pipeline

Lundbeck’s key products shine in Q2 but problems remain

Faces increasing patent losses

Lundbeck snaps up Abide Therapeutics for $400m

Also acquires its lead drug for Tourette’s syndrome

GSK to reverse ‘no KOLs’ policy, admitting it has hit marketing

Company seeking to revive lacklustre marketing performance

Transparency and accountability: tackling opacity and blame head-on

Let’s be honest, big pharma lacks trust and many love to hate it. Faceless corporations tainted by past own-goals, profiteering, cherry-picked data and spun claims - so goes the lazy...